MA39912B1 - Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme. - Google Patents

Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme.

Info

Publication number
MA39912B1
MA39912B1 MA39912A MA39912A MA39912B1 MA 39912 B1 MA39912 B1 MA 39912B1 MA 39912 A MA39912 A MA 39912A MA 39912 A MA39912 A MA 39912A MA 39912 B1 MA39912 B1 MA 39912B1
Authority
MA
Morocco
Prior art keywords
bpco
neuralgia
thiazole
asthma
pain
Prior art date
Application number
MA39912A
Other languages
English (en)
Other versions
MA39912A (fr
Inventor
Andrea Aramini
Gianluca Bianchini
Laura Brandolini
Andrea Beccari
Samuele Lillini
Giuseppe Nano
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of MA39912A publication Critical patent/MA39912A/fr
Publication of MA39912B1 publication Critical patent/MA39912B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/42—One oxygen atom attached in position 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MA39912A 2014-06-23 2015-06-23 Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme. MA39912B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14173502 2014-06-23
PCT/EP2015/064146 WO2015197640A1 (fr) 2014-06-23 2015-06-23 Dérivés du 2-aryl-4-hydroxy-1,3-thiazole utilisables comme inhibiteurs du trpm8 dans le traitement de la névralgie, de la douleur, de la broncho-pneumopathie chronique obstructive et de l'asthme
EP15730801.6A EP3157918B1 (fr) 2014-06-23 2015-06-23 Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme.

Publications (2)

Publication Number Publication Date
MA39912A MA39912A (fr) 2017-04-26
MA39912B1 true MA39912B1 (fr) 2019-05-31

Family

ID=50979632

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39912A MA39912B1 (fr) 2014-06-23 2015-06-23 Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme.

Country Status (22)

Country Link
US (2) US10196368B2 (fr)
EP (1) EP3157918B1 (fr)
JP (1) JP6557332B2 (fr)
KR (1) KR102493005B1 (fr)
CN (1) CN106660975B (fr)
AU (1) AU2015279272B2 (fr)
CY (1) CY1121624T1 (fr)
DK (1) DK3157918T3 (fr)
EA (1) EA034525B1 (fr)
ES (1) ES2724111T3 (fr)
HR (1) HRP20190819T1 (fr)
HU (1) HUE043586T2 (fr)
LT (1) LT3157918T (fr)
MA (1) MA39912B1 (fr)
ME (1) ME03399B (fr)
PL (1) PL3157918T3 (fr)
PT (1) PT3157918T (fr)
RS (1) RS58590B1 (fr)
SI (1) SI3157918T1 (fr)
SM (1) SMT201900274T1 (fr)
TR (1) TR201905319T4 (fr)
WO (1) WO2015197640A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3184524A1 (fr) 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. Dérivés de 4-hydroxy-2-phenyl-1,3-thiazole-méthanone en tant qu'antagonistes du trpm8
EP3409277A1 (fr) * 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Inhibiteurs il-8 destinés à être utilisés dans le traitement et/ou la prévention d'infections secondaires bactériennes
EP3782702A1 (fr) * 2019-08-21 2021-02-24 AC BioScience SA Compositions et leur utilisation pour le traitement de maladies infectieuses et du cancer
EP3907214A1 (fr) * 2020-05-04 2021-11-10 Dompe' Farmaceutici S.P.A. Co-cristal de kétoprofène, de lysine et de gabapentine, compositions pharmaceutiques et leur utilisation médicale
EP4759311A1 (fr) 2024-12-13 2026-06-17 Dompé farmaceutici SpA Inhibiteurs de trpm8 destinés à être utilisés dans la prévention ou le traitement de lésions articulaires, de la dégénérescence articulaire et/ou d'une inflammation articulaire provoquée par l'arthrose

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2073981C (fr) * 1990-11-30 2002-01-08 Shiro Kondo Derives de 2-arylthiazole et composition pharmaceutique a base de ces derives
EP1802600A1 (fr) 2004-10-13 2007-07-04 Bayer HealthCare AG Derives de 4-benzyloxy-phenylmethylamide substitues utilises comme antagonistes de recepteur 1 au froid active par menthol (cmr-1) pour traiter des troubles urologiques
WO2007017092A1 (fr) 2005-08-04 2007-02-15 Bayer Healthcare Ag Derives amides d'acide 4-benzyloxy-benzoique substitue
WO2007017093A1 (fr) 2005-08-04 2007-02-15 Bayer Healthcare Ag Derives amides d'acide 2-benzyloxy-benzoique substitue
WO2007017094A1 (fr) 2005-08-04 2007-02-15 Bayer Healthcare Ag Dérivés benzyloxyphénylméthylcarbamate substitués
WO2007080109A1 (fr) 2006-01-16 2007-07-19 Bayer Healthcare Ag Dérivés de benzyloxyphénylméthylurée substitués
JP5404388B2 (ja) 2006-05-10 2014-01-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 冷メントール受容体−１拮抗薬
PA8790401A1 (es) 2007-07-18 2009-03-31 Janssen Pharmaceutica Nv Sulfonamidas como moduladores de trpm8
WO2010103381A1 (fr) 2009-03-13 2010-09-16 Glenmark Pharmaceuticals S.A. Dérivés de pipéridine spirocycliques en tant que modulateurs de trpm8
CN102427810A (zh) 2009-05-01 2012-04-25 拉夸里亚创药株式会社 作为trpm8拮抗剂的氨磺酰基苯甲酸衍生物
US9585875B2 (en) * 2011-12-19 2017-03-07 Dompé Farmaceutici S.P.A. TRPM8 antagonists
EP2606888A1 (fr) * 2011-12-19 2013-06-26 Dompe' S.P.A. Antagonistes du TRPM8

Also Published As

Publication number Publication date
AU2015279272A2 (en) 2017-01-19
WO2015197640A1 (fr) 2015-12-30
EP3157918A1 (fr) 2017-04-26
KR102493005B1 (ko) 2023-01-30
AU2015279272B2 (en) 2018-01-18
ES2724111T3 (es) 2019-09-06
HRP20190819T1 (hr) 2019-06-28
JP6557332B2 (ja) 2019-08-07
PL3157918T3 (pl) 2019-08-30
US11046662B2 (en) 2021-06-29
SMT201900274T1 (it) 2019-07-11
JP2017520623A (ja) 2017-07-27
SI3157918T1 (sl) 2019-05-31
CN106660975B (zh) 2019-12-31
US20190106395A1 (en) 2019-04-11
LT3157918T (lt) 2019-05-27
MA39912A (fr) 2017-04-26
PT3157918T (pt) 2019-05-09
TR201905319T4 (tr) 2019-05-21
DK3157918T3 (da) 2019-05-13
CN106660975A (zh) 2017-05-10
HUE043586T2 (hu) 2019-08-28
KR20170031664A (ko) 2017-03-21
AU2015279272A1 (en) 2017-01-12
RS58590B1 (sr) 2019-05-31
CY1121624T1 (el) 2020-07-31
ME03399B (fr) 2020-01-20
US10196368B2 (en) 2019-02-05
EA034525B1 (ru) 2020-02-17
EA201790072A1 (ru) 2017-11-30
EP3157918B1 (fr) 2019-03-27
US20170190678A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
IL279752B (en) Polycyclic compounds and use thereof in the treatment of immune disorders
LTC3057969I2 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
IL256166B (en) Compounds for use in treating neuromuscular disorders
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
HUE053946T2 (hu) 4'-Fluor-nukleozidok, 4'-fluor-nukleotidok és analógjaik HCV kezelésére
PL3896064T3 (pl) Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego
LT3240554T (lt) Blautia stercosis ir wexlerae, skirtos naudoti uždegiminių ir autoimuninių ligų gydymui
MA50482A (fr) Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
MA41031A (fr) Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
EP3298140A4 (fr) Compositions pour le traitement d'états de calcification pathologique, et méthodes les utilisant
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
IL252418B (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
IL280827A (en) Integrin alpha 4 antagonists and compositions comprising same for use in treating ocular conditions
ZA201901826B (en) Cell suspension for use in the treatment of lower extremity peripheral artery disease
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
HUE036084T2 (hu) Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél
EP2967062A4 (fr) Déséthylhydroxychloroquine pour le traitement de maladies associées avec l'inflammation
CY1126258T1 (el) Ενωσεις ινδολινονης και χρηση αυτων στη θεραπεια ινωτικων ασθενειων
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
HUE046924T2 (hu) Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra
EP3650018A4 (fr) Application de cannabidiol dans le traitement de l'hypertension pulmonaire
EP3185862A4 (fr) Composés d'analogues de la métallothionéine de protection, leurs compositions et leur utilisation dans le traitement de maladies pathogènes